Study identifier:D961HL00020
ClinicalTrials.gov identifier:NCT02477475
EudraCT identifier:N/A
CTIS identifier:N/A
NEXIUM Capsule Specific Clinical Experience Investigation (S-CEI) to investigate treatment response to NEXIUM in patients with reflux esophagitis (RE) - Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing based on Patient Clinical Outcomes
reflux esophagitis
N/A
No
-
All
1595
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2017 by AstraZeneca
AstraZeneca
-
The objective of this investigation is to collect following data in patients given NEXIUM capsule (NEXIUM) in usual post-marketing use.
Primary objective To investigate treatment response to NEXIUM in patients with reflux esophagitis (RE). Secondary objectives To investigate following items in patients with RE: 1. Patient satisfactory level of the treatment for RE 2. Health-related quality of life (HRQOL) 3. Severity and frequency of RE symptoms reported by physicians 4. Endoscopic healing rate 5. Development of ADRs
Arms | Assigned Interventions |
---|---|
NEXIUM Oral dose 20mg/day | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.